Company Overview
Snapshot
Founded in August 2021 by Zeev Russak and Ofer Peleg, Infiniplex operates with 11–50 employees. The company has secured $1.1 million across one funding round.
Business overview
Infiniplex is a Health Tech & Life Sciences company focused on cancer monitoring and screening. The company develops technology to utilize routine blood testing for screening genetic tumor biomarkers, aiming to provide preemptive, preventive, and follow-up cancer screenings at an accessible and affordable cost. Infiniplex's core product, Chiffon, seeks to identify common and rare cancer types through standard blood tests, leveraging existing laboratory equipment and expertise. It operates within the diagnostics, oncology, and medical technologies sectors, serving the healthcare industry with a B2B business model.
Strategic signal
In May 2022, Infiniplex secured an investment from Terra Venture Partners, indicating early investor confidence in its innovative approach to cancer diagnostics. This funding suggests a positive signal for the company's potential to advance its mission of making cancer screening more accessible and affordable through routine blood tests, positioning it for further development in the Health Tech & Life Sciences sector.
Log in to access full profile ›Company Intelligence Q&A
- When was Infiniplex founded?
- Infiniplex was founded in August 2021.
- Who are the founders of Infiniplex?
- The founders of Infiniplex are Zeev Russak and Ofer Peleg.
- What is Infiniplex's primary focus?
- Infiniplex focuses on utilizing routine blood testing to screen for genetic tumor biomarkers and to offer preemptive, preventive, and follow-up cancer screenings at an accessible and affordable cost.
- How much capital has Infiniplex raised to date?
- Infiniplex has raised $1.1 million across one funding round.
- Which investor participated in Infiniplex's funding round?
- In May 2022, Terra Venture Partners participated in a funding round for Infiniplex.